PARP1-TRIM44-MRN loop dictates the response to PARP inhibitors

PARP inhibitors (PARPi) show selective efficacy in tumors with homologous recombination repair (HRR)-defects but the activation mechanism of HRR pathway in PARPi-treated cells remains enigmatic. To unveil it, we searched for the mediator bridging PARP1 to ATM pathways by screening 211 human ubiquitin-related proteins. We discovered TRIM44 as a crucial mediator that recruits the MRN complex to damaged chromatin, independent of PARP1 activity. TRIM44 binds PARP1 and regulates the ubiquitination-PARylation balance of PARP1, which facilitates timely recruitment of the MRN complex for DSB repair. Upon exposure to PARPi, TRIM44 shifts its binding from PARP1 to the MRN complex via its ZnF UBP domain. Knockdown of TRIM44 in cells significantly enhances the sensitivity to olaparib and overcomes the resistance to olaparib induced by 53BP1 deficiency. These observations emphasize the central role of TRIM44 in tethering PARP1 to the ATM-mediated repair pathway. Suppression of TRIM44 may enhance PARPi effectiveness and broaden their use even to HR-proficient tumors.

Authors

Institutions

Publication Details

Journal
Nucleic Acids Research
Published
2024-09-01
DOI
https://doi.org/10.1093/nar/gkae756
Citations
2
Primary Topic
PARP inhibition in cancer therapy
Type
article
Field-Weighted Citation Impact
0.57

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

PARP1-TRIM44-MRN loop dictates the response to PARP inhibitors

Ho Chul Kang, Seo Yun Lee, Soon Sang Park, Hyeseong Cho et al.
2 citations
Nucleic Acids Research
PARP inhibition in cancer therapy
0.57
article

PARP1-TRIM44-MRN loop dictates the response to PARP inhibitors

Ho Chul Kang, Seo Yun Lee, Soon Sang Park, Hyeseong Cho, Sunwoo Min, Yeon‐Ji Park, Yonghyeon Kim, Yungyeong Heo, Jae‐Ho Lee, Tae Jun Park, Soyeon Kim, Jae‐Hoon Ji
article en
2 citations

Abstract

PARP inhibitors (PARPi) show selective efficacy in tumors with homologous recombination repair (HRR)-defects but the activation mechanism of HRR pathway in PARPi-treated cells remains enigmatic. To unveil it, we searched for the mediator bridging PARP1 to ATM pathways by screening 211 human ubiquitin-related proteins. We discovered TRIM44 as a crucial mediator that recruits the MRN complex to damaged chromatin, independent of PARP1 activity. TRIM44 binds PARP1 and regulates the ubiquitination-PARylation balance of PARP1, which facilitates timely recruitment of the MRN complex for DSB repair. Upon exposure to PARPi, TRIM44 shifts its binding from PARP1 to the MRN complex via its ZnF UBP domain. Knockdown of TRIM44 in cells significantly enhances the sensitivity to olaparib and overcomes the resistance to olaparib induced by 53BP1 deficiency. These observations emphasize the central role of TRIM44 in tethering PARP1 to the ATM-mediated repair pathway. Suppression of TRIM44 may enhance PARPi effectiveness and broaden their use even to HR-proficient tumors.

Nucleic Acids ResearchVol. 52(19)
Hallym University (KR), The University of Texas at San Antonio Health Science Center (US), Chungnam National University (KR), The University of Texas at San Antonio (US), Ajou University (KR)
Ministry of Health and Welfare, National Research Foundation, Ulsan National Institute of Science and Technology, Korea Health Industry Development Institute, National Research Foundation of Korea
Good health and well-being
Openalex Percentile: Top 28%
PARP inhibition in cancer therapy
0.57
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.